

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

IN RE: GENERIC PHARMACEUTICALS  
PRICING ANTITRUST LITIGATION

MDL NO. 2724  
16-MD-2724

*IN RE: CLOBETASOL CASES*

DPP CASE: 16-CB-27241  
EPP CASE: 16-CB-27242

*IN RE: CLOMIPRAMINE CASES*

DPP CASE: 16-CM-27241  
EPP CASE: 16-CM-27242

THIS DOCUMENT RELATES TO:  
*DPP AND EPP BELLWETHER ACTIONS*

HON. CYNTHIA M. RUFFE

**THE BELLWETHER PARTIES' JOINT STIPULATION RELATED TO  
EPP *CLOMIPRAMINE* AND DPP *CLOBETASOL* CASES**

WHEREAS, pursuant to Pretrial Order No. 294 (MDL Doc. 3282), the parties to the bellwether cases captioned above have been preparing these matters for trials to commence in August 2025;

WHEREAS, the Court's April 23, 2025 Order (MDL Doc. 3347) set two of the four cases for an August 4, 2025 trial pool, with the EPP *Clobetasol* case to begin August 4, 2025, and the DPP *Clomipramine* case to follow;

WHEREAS, the parties agree that focusing their pretrial preparations on the cases currently scheduled for trial – EPP *Clobetasol* and DPP *Clomipramine* – will maximize efficiency and conserve the resources of the parties and the Court;

WHEREAS, the parties agree that, subject to Court approval, adjournment of the pretrial schedule for EPP *Clomipramine* and DPP *Clobetasol* is appropriate to conserve the resources of the parties and the Court;

WHEREAS, the parties further agree that, subject to Court approval, in the absence of settlements after the initial set of trials or other direction from the Court, a deadline for resumption of pretrial preparations of the EPP *Clomipramine* and DPP *Clobetasol* cases is appropriate;

NOW THEREFORE, the undersigned Bellwether Parties hereby **STIPULATE AND AGREE** as follows:

1. Effective May 9, 2025, the deadlines in PTO 294 shall be adjourned for EPP *Clomipramine* and DPP *Clobetasol*, except as to proceedings relating to summary judgment, which shall continue for all four DPP/EPP bellwether cases.
2. Provided the parties to either EPP *Clomipramine* or DPP *Clobetasol* are unable to reach settlement, the pretrial activities required by PTO 294 shall resume for one or both cases with Motions on Disputed Legal Issues due **45 days** after the jury reaches a verdict in the Court's last trial of either EPP *Clobetasol* or DPP *Clomipramine*.
3. Provided one or both of EPP *Clomipramine* or DPP *Clobetasol* resumes pretrial activities as described above, the parties to that action or those actions will negotiate a revised pretrial schedule using the same time intervals provided in PTO 294 starting with Motions on Disputed Legal Issues, subject to adjustments that account for the Court's schedule (including available trial dates for EPP *Clomipramine* and/or DPP *Clobetasol*) and other appropriate considerations such as holidays.
4. For instance, events that will occur one week after the May 9, 2025 deadline for

Motions on Disputed Legal issues in EPP Clobetasol and DPP Clomipramine (*i.e.*, May 16, 2025 exchanges of objections to witness lists, motions for limited discovery on authenticity and admissibility for good cause shown, exchanges of objections and counter-designations, exchanges of drafts of stipulations of undisputed facts, and exchanges of drafts of jury instructions and verdict forms), would occur one week after the Motions on Disputed Legal Issues in EPP Clomipramine and DPP Clobetasol (*e.g.*, if Motions on Disputed Legal Issues are due on October 13, 2025, those other events are due on October 20, 2025).

**IT IS SO STIPULATED.**

Dated: May 9, 2025

/s/ Dianne M. Nast

Dianne M. Nast  
NASTLAW LLC  
1101 Market Street, Suite 2801  
Philadelphia, PA 19107  
(215) 923-9300  
dnast@nastlaw.com

***Lead and Liaison Counsel for the  
Direct Purchaser Plaintiffs***

/s/ Roberta D. Liebenberg

Roberta D. Liebenberg  
FINE, KAPLAN AND BLACK, R.P.C.  
One South Broad Street, 23rd Floor  
Philadelphia, PA 19107  
215-567-6565  
rliebenberg@finekaplan.com

***Lead and Liaison Counsel for the  
End-Payer Plaintiffs***

/s/ Seth A. Moskowitz

Seth A. Moskowitz  
Sheron Korpus  
Seth Davis  
David M. Max  
**KASOWITZ BENSON TORRES LLP**  
1633 Broadway  
New York, NY 10019  
Telephone: (212) 506-1700  
Facsimile: (212) 506-1800  
smoskowitz@kasowitz.com  
skorpus@kasowitz.com  
sdavis@kasowitz.com  
dmax@kasowitz.com

*Counsel for Defendants Actavis Holdco U.S.,  
Inc. and Actavis Pharma, Inc.*

**WILSON SONSINI GOODRICH &  
ROSATI, P.C.**

/s/ Chul Pak

Chul Pak  
Michael Sommer  
1301 Avenue of the Americas, 40th Floor  
New York, New York 10019  
Telephone: (212) 999-5800  
Facsimile: (866) 974-7329

Email: cpak@wsgr.com  
Email: msommer@wsgr.com

Seth C. Silber  
Jeffrey C. Bank  
Wilson Sonsini Goodrich & Rosati, P.C.  
1700 K Street NW, Fifth Floor  
Washington, DC 20006  
Telephone: (202) 973-8800  
Facsimile: (866) 974-7329  
Email: ssilber@wsgr.com  
Email: jbank@wsgr.com

*Counsel for Mylan Defendants*

/s/ Clifford Katz  
Clifford Katz  
Damon Suden  
**KELLEY DRYE & WARREN LLP**  
3 World Trade Center  
175 Greenwich Street  
New York, NY 10007  
Telephone: (212) 808-7800  
Facsimile: (212) 808-7897  
ckatz@kellydrye.com  
dsuden@kellydrye.com

*Counsel for Defendants Wockhardt USA LLC  
and Morton Grove Pharmaceuticals, Inc.*

/s/ John M. Taladay  
John M. Taladay  
Christopher P. Wilson  
JoAnna Adkisson  
**BAKER BOTTS LLP**  
700 K Street NW  
Washington, DC 20001  
Telephone: (202) 639-7700  
Facsimile: (202) 639-7890  
john.taladay@bakerbotts.com  
christopher.wilson@bakerbotts.com  
joanna.adkisson@bakerbotts.com

Lauri A. Kavulich  
**CLARK HILL PLC**  
2001 Market St, Suite 2620

Philadelphia, PA 19103  
Telephone: (215) 640-8500  
Facsimile: (215) 640-8501  
lkavulich@clarkhill.com

Lindsay S. Fouse  
**CLARK HILL PLC**  
301 Grant St, 14th Floor  
Pittsburgh, PA 15219  
Telephone: (412) 394-7711  
Facsimile: (412) 394-2555  
lfouse@clarkhill.com

*Counsel for Defendant Taro Pharmaceuticals  
U.S.A., Inc.*

**CERTIFICATE OF SERVICE**

I hereby certify that on May 9, 2025, a true and correct copy of the foregoing was served via CM/ECF upon all counsel of record.

Dated: May 9, 2025

/s/ Seth A. Moskowitz